Helicobacter pylori (H. pylori) is a cork-screw-spiral-like gram-negative bacterium that has adapted to grow in the human stomach. The prevalence of H. pylori infection worldwide is approximately 66%, and in developing countries, it is as high as 80% – 90%. The testing and treatment of H. pylori is very important as it has been estimated that up to 20% of people infected with H. pylori will develop ulcers which may lead to specific cancers. MP Diagnostics ASSURE H. pylori Rapid Test and Helico Blot 2.1 Western Blot incorporate a unique marker, CIM, which is used to detect the current infection of H. pylori bacteria. CIM stands for Current Infection Marker which is actually a H. pylori-specific protein. The nucleotide sequence of the CIM antigen is homologous to a conserved secreted protein. This protein has been found to be highly immunogenic for detection of H. pylori infected patients with high Positive Predictive Value of >90%. It has been coined as Current Infection Marker because IgG antibodies for CIM have been found in patients with active H. pylori infection. These patients are confirmed to have active H. pylori infection by two or more active infection diagnostic tests such as rapid urease test, culture, histology, and Urea Breath Test. With CIM-based products, no additional tests are needed for detecting current H. pylori infection. Read more
https://clinlabint.com/wp-content/uploads/sites/2/2020/08/C302_MPbiomedicals.jpg831503wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-08-26 09:19:532021-01-08 11:28:57H. pylori rapid test
Rapid, simultaneous detection of respiratory pathogens
The Respiratory Multiplex Array is intended for the simultaneous detection of 22 bacterial and viral respiratory pathogens in individuals suspected of Respiratory Tract Infections. The ability to simultaneously detect these in one sample provides clinicians with a complete patient profile, enabling faster and more appropriate treatment decisions.
The Respiratory Multiplex Array is based on a combination of multiplex PCR, biochip hybridization and chemiluminescence detection using the Evidence Investigator analyser. The array can run 54 samples simultaneously in five hours. Identifying multiple pathogens will provide a rapid and more cost-effective diagnostic tool than current methods – which only look for single pathogens – thus reducing the time from presentation to treatment and minimizing sample requirements. Save time and costs associated with single pathogen detection by using the Respiratory Multiplex Array.
Randox is helping in the fight against unwanted disease
Sexually Transmitted Infections (STIs) have become a wearisome issue for healthcare systems across the globe. Early and correct diagnosis of STIs is essential as they can lead to other major health issues. Undiagnosed STIs can spread uncontrollably.
With the ability to simultaneously detect 10 STI pathogens, the STI array far exceeds other STI tests currently available. Its rapid multiplexing capabilities allow it to detect the following pathogens: chlamydia trachomonas, neisseria gonorrhea, trichomonas vaginalis, treponema pallidum, herpes simplex I, herpes simplex II, mycoplasma hominis, mycoplasma genitalium, ureaplasm urealyticum, haemophilus ducreyi.
Through simultaneous testing for multiple STI pathogens, specific viral, protozoan or bacterial pathogens can be identified, thus resulting in a targeted antibiotic response. This can also identify secondary infections which could have been missed.
Resistant to Xylene, MEK, IPA, DMSO, etc, Laboratory Labelling Specialists CILS have launched the ultimate solvent-resistant, computer printable durable label – Perfect for microscope slides, HPLC columns, tissue cassettes, vials, tubes etc.
Printable straight from a standard Laser or Thermal Transfer printer, variable data (batch no’s, barcodes etc) can be added ‘in minutes’, saving time and eliminating the risk of smudged/illegible handwritten data.
The specially formulated CILS-8100S computer imprintable surface coating ensures all variable data remains clear and legible under extreme solvent exposure without any secondary laminates or tape.
For more information on the CILS solvent resistant laboratory label range, visit:http://www.cils-international.com/content/cils-ultra-solvent-resistant-labels Read more
https://clinlabint.com/wp-content/uploads/sites/2/2020/08/cils_01.jpg1241503wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-08-26 09:19:532021-01-08 11:28:56CILS-8100S The Most Solvent-Resistant CILS Label Yet
BIO-FLASH is a rapid-response chemiluminescent analyser for use by clinical reference and hospital laboratories. It offers full automation of a broad menu of highly accurate QUANTA Flash immunoassays for autoimmunity testing. Tests that previously required significant hands-on time can now be automated on an intuitive and rapid system. BIO-FLASH and the QUANTA Flash reagents are classified as moderately complex under the Clinical Laboratories Improvements Act (CLIA), making the system accessible to a wide range of laboratories and their staff. The first result is generated in as little as 30 minutes, with additional results generated one per minute thereafter. The analyser incorporates chemiluminescent technology, representing an important advance in accuracy and precision for immunoassay testing. Other benefits of the system include an increased analytical measuring range, onboard dilution and stored calibration. A comprehensive menu of QUANTA Flash reagents is available, including tests to aid in the diagnosis of celiac disease, vasculitis, antiphospholipid syndrome and connective tissue diseases. This menu will continue to expand as INOVA develops additional autoimmune assays. Read more
A urinary cytokeratin test (lateral flow) for bladder cancer is now available. Cytokeratin proteins have been implicated as tumour cell activity markers and have demonstrated clinical utility in different epithelial cell carcinomas. UBC® Rapid is a POC test that measures soluble cytokeratin 8/18 fragments in voided urine. It has been showed to increase the detection of new cases of bladder cancer. UBC Rapid can also be used for surveillance after primary surgery and as predictor of recurrence. Studies have shown that the test is a useful adjunct tool to cystoscopy in the evaluation of patients at risk of bladder cancer. The combination UBC® Rapid/OMEGA Reader increases the sensitivity and specificity, making the test a useful marker to identify bladder cancer patients. The UBC® Rapid does not require expert analysis or laboratory time and provides unambiguous results during the patient visit. Its cost is low compared to cytology. Read more
https://clinlabint.com/wp-content/uploads/sites/2/2020/08/C315_IDL_UBC-Rapid.jpg1001503wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-08-26 09:19:532021-01-08 11:28:56Urinary POC test for bladder cancer
Surra is a trypanosomiasis caused by Trypanosoma evansi. It is the most widely geographically distributed hemoprotozoan parasite. T. evansi affects domestic animals such as camels, horses, cattles, buffaloes, small ruminants and dogs. It is mechanically transmitted by hemophagus flies, such as tabanus or Stomoxys. Wild animals can act as reservoir hosts. Surra causes severe anemia, edema, various nerological disorders resulting into death of infected animals, and immunodeficiencies leading to increased susceptibility to other diseases or vaccination failure. A serological test provides the most sensitive way to detect the infection, especially in chronic cases, with healthy carriers or when the parasitemia is low. The Surra Sero K-SeT is the first rapid diagnostic test for the detection of antibodies specific to Trypanosoma evansi in animal whole blood or serum. Fast and accurate, it is suitable for laboratories as well as field testing and requires minimal sample handling.
https://clinlabint.com/wp-content/uploads/sites/2/2020/08/C317_Coris_SurraSeroK-SeT2.jpg1271503wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-08-26 09:19:532021-01-08 11:28:56Rapid test for animal Trypanosomiasis
In line with current clinical needs, Diazyme’s new 25-Hydroxy Vitamin D Assay measures total true 25-Hydroxy Vitamin D levels (D2 + D3 levels) in both serum and plasma samples. Furthermore, the assay fully automates the removal of non-specific protein binding and cross reactivity that may occur in competing assays, thereby assuring results will be both precise and accurate. The 25-Hydroxy Vitamin D assay is both fast and flexible with complete testing results in under 2 hours. The test is user-friendly and can be used manually or easily adapted for use on a wide range of fully automated microtitre plate readers, making it suitable for use in laboratories of all sizes and testing needs. Traditionally, testing of Vitamin D levels has been predominantly used for the diagnosis and management of patients with Vitamin D deficiency. Recent clinical studies though have linked Vitamin D deficiency to various diseases including cancers, cardiovascular disease, diabetes, osteoporosis, multiple sclerosis, Alzheimer’s disease and all-cause mortality. This new understanding of the importance of Vitamin D levels has driven an increase in the number of physician requests for total 25-Hydroxy Vitamin D tests in the United States and worldwide. The assay takes a much shorter time and can be fully automated when it is run on ELISA instruments such as the Dynex DS2® and DSX® platforms.
Collagen SRP (Synthetic Reactive Peptide) is a synthetic type 1 collagen-like liquid polypeptide (PHG) that self-assembles into a helix to form fibrils. Synthetic collagen may be useful in laboratories investigating platelet function and reactivity, platelet activation, and cellular analysis. Research laboratories may utilize Collagen SRP to assess aspirin reactivity, detect multiple antiplatelet agents and to investigate metabolized and spiked samples. Collagen SRP will help save time, standardize results and obtain predictable and reproducible results. It does not contain any human, animal or bacterial source material eliminating infectious disease risk. Collagen SRP is for research use only (RUO) and not for use in diagnostic tests, assays or procedures.
Two new ELISAs provide highly sensitive and specific screening for Borrelia antibodies in the serological diagnosis of Lyme disease. The Anti-Borrelia Select ELISA (IgG) and the Anti-Borrelia Select ELISA (IgM) are based on unique combinations of highly specific recombinant antigens from different Borrelia species. The IgG ELISA includes VlsE, which is the most important target antigen for the detection of Borrelia-specific IgG antibodies. All antigens contained in the assay substrate have been carefully selected for their diagnostic value and mixed in optimized concentrations to ensure maximum test sensitivity and specificity. Moreover, many of the antigens have been modified by molecular manipulation to boost their diagnostic performance. The most important component of the IgM ELISA is covalently bound, recombinant dimeric OspC (OspC advanced), which is exclusive to this ELISA. OspC advanced represents the biologically active form of the antigen and provides over 30% higher specificity than traditionally used monomeric forms, while maintaining a high sensitivity. Since antibodies against OspC are produced by 90% of infected persons, inclusion of this optimized antigen significantly enhances the performance of the test in early-stage borreliosis screening. The ELISAs yield significantly fewer cross reactions than lysate-based tests, for example in patients with autoimmune diseases or other infections such as Treponema pallidum. The inclusion of antigens from different human pathogenic Borrelia species ensures reliable results regardless of the infecting species. The Anti-Borrelia Select ELISAs are part of a complete package from EUROIMMUN for borreliosis diagnostics, which also includes immunoblots for the confirmatory diagnostic step, indirect immunofluorescence tests, CSF tests, avidity tests and comprehensive automation concepts for all products.
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
H. pylori rapid test
, /in Product News /by 3wmediaHelicobacter pylori (H. pylori) is a cork-screw-spiral-like gram-negative bacterium that has adapted to grow in the human stomach. The prevalence of H. pylori infection worldwide is approximately 66%, and in developing countries, it is as high as 80% – 90%. The testing and treatment of H. pylori is very important as it has been estimated that up to 20% of people infected with H. pylori will develop ulcers which may lead to specific cancers. MP Diagnostics ASSURE H. pylori Rapid Test and Helico Blot 2.1 Western Blot incorporate a unique marker, CIM, which is used to detect the current infection of H. pylori bacteria. CIM stands for Current Infection Marker which is actually a H. pylori-specific protein. The nucleotide sequence of the CIM antigen is homologous to a conserved secreted protein. This protein has been found to be highly immunogenic for detection of H. pylori infected patients with high Positive Predictive Value of >90%. It has been coined as Current Infection Marker because IgG antibodies for CIM have been found in patients with active H. pylori infection. These patients are confirmed to have active H. pylori infection by two or more active infection diagnostic tests such as rapid urease test, culture, histology, and Urea Breath Test. With CIM-based products, no additional tests are needed for detecting current H. pylori infection.
Read more
Respiratory Multiplex Array
, /in Product News /by 3wmediaRapid, simultaneous detection of respiratory pathogens
The Respiratory Multiplex Array is intended for the simultaneous detection of 22 bacterial and viral respiratory pathogens in individuals suspected of Respiratory Tract Infections. The ability to simultaneously detect these in one sample provides clinicians with a complete patient profile, enabling faster and more appropriate treatment decisions.
The Respiratory Multiplex Array is based on a combination of multiplex PCR, biochip hybridization and chemiluminescence detection using the Evidence Investigator analyser. The array can run 54 samples simultaneously in five hours. Identifying multiple pathogens will provide a rapid and more cost-effective diagnostic tool than current methods – which only look for single pathogens – thus reducing the time from presentation to treatment and minimizing sample requirements. Save time and costs associated with single pathogen detection by using the Respiratory Multiplex Array.
Website: http://www.randox.com/respiratory-molecular-test.php
Email: marketing@randox.com
Read more
STI Multiplex Array
, /in Product News /by 3wmediaRandox is helping in the fight against unwanted disease
Sexually Transmitted Infections (STIs) have become a wearisome issue for healthcare systems across the globe. Early and correct diagnosis of STIs is essential as they can lead to other major health issues. Undiagnosed STIs can spread uncontrollably.
With the ability to simultaneously detect 10 STI pathogens, the STI array far exceeds other STI tests currently available. Its rapid multiplexing capabilities allow it to detect the following pathogens: chlamydia trachomonas, neisseria gonorrhea, trichomonas vaginalis, treponema pallidum, herpes simplex I, herpes simplex II, mycoplasma hominis, mycoplasma genitalium, ureaplasm urealyticum, haemophilus ducreyi.
Through simultaneous testing for multiple STI pathogens, specific viral, protozoan or bacterial pathogens can be identified, thus resulting in a targeted antibiotic response. This can also identify secondary infections which could have been missed.
Website: http://www.randox.com/sti-multiplex-pcr-molecular-test.php
Email: marketing@randox.com
Read more
CILS-8100S The Most Solvent-Resistant CILS Label Yet
, /in Product News /by 3wmediaResistant to Xylene, MEK, IPA, DMSO, etc, Laboratory Labelling Specialists CILS have launched the ultimate solvent-resistant, computer printable durable label – Perfect for microscope slides, HPLC columns, tissue cassettes, vials, tubes etc.
Printable straight from a standard Laser or Thermal Transfer printer, variable data (batch no’s, barcodes etc) can be added ‘in minutes’, saving time and eliminating the risk of smudged/illegible handwritten data.
The specially formulated CILS-8100S computer imprintable surface coating ensures all variable data remains clear and legible under extreme solvent exposure without any secondary laminates or tape.
For more information on the CILS solvent resistant laboratory label range, visit:http://www.cils-international.com/content/cils-ultra-solvent-resistant-labels
Read more
Chemiluminescent analyser
, /in Product News /by 3wmediaBIO-FLASH is a rapid-response chemiluminescent analyser for use by clinical reference and hospital laboratories. It offers full automation of a broad menu of highly accurate QUANTA Flash immunoassays for autoimmunity testing. Tests that previously required significant hands-on time can now be automated on an intuitive and rapid system. BIO-FLASH and the QUANTA Flash reagents are classified as moderately complex under the Clinical Laboratories Improvements Act (CLIA), making the system accessible to a wide range of laboratories and their staff. The first result is generated in as little as 30 minutes, with additional results generated one per minute thereafter. The analyser incorporates chemiluminescent technology, representing an important advance in accuracy and precision for immunoassay testing. Other benefits of the system include an increased analytical measuring range, onboard dilution and stored calibration. A comprehensive menu of QUANTA Flash reagents is available, including tests to aid in the diagnosis of celiac disease, vasculitis, antiphospholipid syndrome and connective tissue diseases. This menu will continue to expand as INOVA develops additional autoimmune assays.
Read more
Urinary POC test for bladder cancer
, /in Product News /by 3wmediaA urinary cytokeratin test (lateral flow) for bladder cancer is now available. Cytokeratin proteins have been implicated as tumour cell activity markers and have demonstrated clinical utility in different epithelial cell carcinomas. UBC® Rapid is a POC test that measures soluble cytokeratin 8/18 fragments in voided urine. It has been showed to increase the detection of new cases of bladder cancer. UBC Rapid can also be used for surveillance after primary surgery and as predictor of recurrence. Studies have shown that the test is a useful adjunct tool to cystoscopy in the evaluation of patients at risk of bladder cancer. The combination UBC® Rapid/OMEGA Reader increases the sensitivity and specificity, making the test a useful marker to identify bladder cancer patients. The UBC® Rapid does not require expert analysis or laboratory time and provides unambiguous results during the patient visit. Its cost is low compared to cytology.
Read more
Rapid test for animal Trypanosomiasis
, /in Product News /by 3wmediaSurra is a trypanosomiasis caused by Trypanosoma evansi. It is the most widely geographically distributed hemoprotozoan parasite. T. evansi affects domestic animals such as camels, horses, cattles, buffaloes, small ruminants and dogs. It is mechanically transmitted by hemophagus flies, such as tabanus or Stomoxys. Wild animals can act as reservoir hosts. Surra causes severe anemia, edema, various nerological disorders resulting into death of infected animals, and immunodeficiencies leading to increased susceptibility to other diseases or vaccination failure. A serological test provides the most sensitive way to detect the infection, especially in chronic cases, with healthy carriers or when the parasitemia is low. The Surra Sero K-SeT is the first rapid diagnostic test for the detection of antibodies specific to Trypanosoma evansi in animal whole blood or serum. Fast and accurate, it is suitable for laboratories as well as field testing and requires minimal sample handling.
Read more
25-Hydroxy vitamin D assay
, /in Product News /by 3wmediaIn line with current clinical needs, Diazyme’s new 25-Hydroxy Vitamin D Assay measures total true 25-Hydroxy Vitamin D levels (D2 + D3 levels) in both serum and plasma samples. Furthermore, the assay fully automates the removal of non-specific protein binding and cross reactivity that may occur in competing assays, thereby assuring results will be both precise and accurate. The 25-Hydroxy Vitamin D assay is both fast and flexible with complete testing results in under 2 hours. The test is user-friendly and can be used manually or easily adapted for use on a wide range of fully automated microtitre plate readers, making it suitable for use in laboratories of all sizes and testing needs. Traditionally, testing of Vitamin D levels has been predominantly used for the diagnosis and management of patients with Vitamin D deficiency. Recent clinical studies though have linked Vitamin D deficiency to various diseases including cancers, cardiovascular disease, diabetes, osteoporosis, multiple sclerosis, Alzheimer’s disease and all-cause mortality. This new understanding of the importance of Vitamin D levels has driven an increase in the number of physician requests for total 25-Hydroxy Vitamin D tests in the United States and worldwide. The assay takes a much shorter time and can be fully automated when it is run on ELISA instruments such as the Dynex DS2® and DSX® platforms.
Read more
Synthetic liquid collagen
, /in Product News /by 3wmediaCollagen SRP (Synthetic Reactive Peptide) is a synthetic type 1 collagen-like liquid polypeptide (PHG) that self-assembles into a helix to form fibrils. Synthetic collagen may be useful in laboratories investigating platelet function and reactivity, platelet activation, and cellular analysis. Research laboratories may utilize Collagen SRP to assess aspirin reactivity, detect multiple antiplatelet agents and to investigate metabolized and spiked samples. Collagen SRP will help save time, standardize results and obtain predictable and reproducible results. It does not contain any human, animal or bacterial source material eliminating infectious disease risk. Collagen SRP is for research use only (RUO) and not for use in diagnostic tests, assays or procedures.
Read more
Borrelia ELISA
, /in Product News /by 3wmediaTwo new ELISAs provide highly sensitive and specific screening for Borrelia antibodies in the serological diagnosis of Lyme disease. The Anti-Borrelia Select ELISA (IgG) and the Anti-Borrelia Select ELISA (IgM) are based on unique combinations of highly specific recombinant antigens from different Borrelia species. The IgG ELISA includes VlsE, which is the most important target antigen for the detection of Borrelia-specific IgG antibodies. All antigens contained in the assay substrate have been carefully selected for their diagnostic value and mixed in optimized concentrations to ensure maximum test sensitivity and specificity. Moreover, many of the antigens have been modified by molecular manipulation to boost their diagnostic performance.
The most important component of the IgM ELISA is covalently bound, recombinant dimeric OspC (OspC advanced), which is exclusive to this ELISA. OspC advanced represents the biologically active form of the antigen and provides over 30% higher specificity than traditionally used monomeric forms, while maintaining a high sensitivity. Since antibodies against OspC are produced by 90% of infected persons, inclusion of this optimized antigen significantly enhances the performance of the test in early-stage borreliosis screening.
The ELISAs yield significantly fewer cross reactions than lysate-based tests, for example in patients with autoimmune diseases or other infections such as Treponema pallidum. The inclusion of antigens from different human pathogenic Borrelia species ensures reliable results regardless of the infecting species.
The Anti-Borrelia Select ELISAs are part of a complete package from EUROIMMUN for borreliosis diagnostics, which also includes immunoblots for the confirmatory diagnostic step, indirect immunofluorescence tests, CSF tests, avidity tests and comprehensive automation concepts for all products.
Read more